Kidney Cancer Drugs Market To Reach $9.90 Billion By 2030

Kidney Cancer Drugs Market Growth & Trends

The global kidney cancer drugs market size is expected to reach USD 9.90 billion in 2030 and is projected to grow at a CAGR of 6.9% from 2024 to 2030. Market growth is largely driven by factors such as the availability of novel drugs and the presence of a strong pipeline. Growth can also be attributed to a rise in the incidence of renal cancer due to the growing geriatric population and changes in lifestyle such as increased smoking and intake of alcohol.

In 2012, kidney cancer was the 13^th most prevalent cancer worldwide, accounting for approximately 2.0% of all adult malignancies. Kidney and renal pelvis cancer make up for 3.8% of all new cancer cases in U.S. Renal cell carcinoma account for over 90.0% of kidney carcinomas. Various forms of cancer treatment methods have been implemented among the currently approved drugs, including immune modulation therapy, cytokine therapy, mTOR inhibitor, and Vascular Endothelial Growth Factor (VEGF) inhibitor.

 Request a free sample copy or view report summary: Kidney Cancer Drugs Market Report

Kidney Cancer Drugs Market Report Highlights

•  Increasing incidence of the disease and rising geriatric population globally are amongst major factors stimulating market growth

• Novel agents have expanded market opportunities through a larger number of patients under treatment and better treatment prospects compared to traditional therapies. The notable clinical profile of immuno-oncology drugs is reflected in their rapid uptake and expansion of indications

• The current treatment landscape in metastatic and advanced RCC will shift from TKI and mTOR inhibitors to specific immuno-oncology agents like immune checkpoint inhibitors (ICI), which have demonstrated positive results on PFS as monotherapy (Opdivo) or combination therapy (Opdivo+Yervoy)

• Emerging markets in Asia Pacific and Middle East and Africa are fueled by increasing expenditure on healthcare, a large untapped patient population base due to rise in the elderly population, and improvement in diagnostic technologies

Kidney Cancer Drugs Market Segmentation

Grand View Research has segmented the global kidney cancer drugs market report based on type, therapy, drug class, route of administration, end use, and region

Kidney Cancer Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Renal cell carcinoma (RCC)

• Transitional cell cancer

• Wilms tumor

• Renal sarcoma

Kidney Cancer Drugs Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted therapy

• Immunotherapy

• Chemotherapy

• Other therapies

Kidney Cancer Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Angiogenesis inhibitors

• Monoclonal antibodies

• mTOR inhibitors

• Cytokine immunotherapy (IL-2)

• Other drug classes

Kidney Cancer Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Intravenous

• Subcutaneous

Kidney Cancer Drugs End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other (Specialty pharmacy and online)

Kidney Cancer Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Kidney Cancer Drugs Market

• Astellas Pharma Inc.

• AstraZeneca PLC

• Bayer AG

• Bristol-Myers Squibb Company

• Eisai Co., Ltd.

• F. Hoffmann-La Roche Ltd.

• GSK plc

• Helsinn Healthcare SA

• Johnson & Johnson Services, Inc.

• Merck & Co., Inc.

• Novartis AG